Q2 2021 Terumo Corp Earnings Call Transcript
Good evening. This is the CEO, Sato. My remarks will focus on the Alliance business, which is one area of effort in our growth strategy. Why? One, because we have received many questions about what will support Terumo's growth after COVID-19? Two, to this point, the state of the business has been somewhat hidden in the shadow of the Cardiac and Vascular business. Three, we have high expectations that the Alliance business will be a new growth driver going forward. Four, the business' performance has now grown to a size that merits some discussion. Five, it is also a new business model, which can be strategically applied to others. That's some of the background for why I will speak about the Alliance business.
Next slide, please. First, I will define what the Alliance business is within Terumo. In Terumo, the B2B business of supplying medical devices to and manufacturing on consignment for pharmaceutical companies is referred to as the Alliance business. Because it is related to providing pharmaceutical companies with core
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |